Thank you, Mark and good afternoon everyone. Before I begin, please note that I will be discussing non-GAAP financial measures, such as EBITDA, adjusted EBITDA, adjusted net income, adjusted EPS, and free cash flow. Our press release, 10-Q and Investor Relations page on the Huron's website have reconciliations of these non-GAAP measures to the most comparable GAAP measures, along with the discussion of why management uses these non-GAAP measures, why management believes they provide useful information to investors regarding our financial condition and operating results. Before discussing our financial results for the quarter, I would like to acknowledge two housekeeping items. First, in the second quarter of 2024, we settled a litigation matter for $15 million, which [indiscernible] pointed. This $15 million settlement gain was recorded as a component of other gains net on our consolidated statement of operations. We have excluded from our non-GAAP measures $11.7 million, which is the value of the settlement gain that exceeds the third-party legal costs incurred during 2024, specific to this litigation matter. Second, I want to make a comment on revenue-generating professional headcount growth. Our year-over-year headcount growth of 13% as of June 30th included the expansion of our India-based Healthcare Managed Services team. Excluding the impact of the India-based Managed Services team, headcount growth was 6%. Now, I'll share some of the key financial results from the second quarter. Revenues for the second quarter of 2024 were a record high, achieving $371.7 million, up 7.2% from $346.8 million in the same quarter of 2023. The increase in revenues for the quarter was driven by solid growth in our healthcare and education segments and included a full quarter contribution of $6.8 million from our GG+A acquisition, which closed during the first quarter of 2024. Net income for the second quarter of 2024 was $37.5 million or $2.03 per diluted share compared to net income of $24.7 million or $1.27 per diluted share for the second quarter of 2023. The increase in net income was driven by the litigation settlement gain I mentioned earlier and revenues that outpaced expenses. Our effective income tax rate in the second quarter of 2024 was 28.1%, which is less favorable than the statutory rate, inclusive of state income taxes, primarily due to certain non-deductible expense items. Adjusted EBITDA was a record $55.7 million in Q2 2024 or 15% of revenues compared to $48.5 million or 14% of revenues in Q2 2023. The increase in adjusted EBITDA for the quarter was primarily due to the increase in segment operating income, excluding the impact of segment restructuring charges. We are proud of our progress in improving margins and we remain confident in our ability to achieve full year mid-teen margins in 2025, consistent with the goal we set forth in our 2022 Investor Day. Adjusted net income was $30.9 million, a record $1.68 per diluted share in Q2 2024 compared to $27 million or $1.38 per diluted share in the second quarter of 2023, resulting in a 22% increase in adjusted diluted earnings per share over Q2 2023. Now, I'll discuss the performance of each of our operating segments. Healthcare segment generated 51% of total company revenues during the second quarter of 2024. This segment posted revenues of $190.1 million, up $16.3 million or 9.4% from the second quarter of 2023. The increase in revenues in the quarter reflects continued strong demand for our digital improvement, culture and organizational excellence, and strategy and innovation offerings. Healthcare's digital and consulting and managed services capabilities grew 15% and 7%, respectively, in the second quarter, reflecting the continued broad-based demand for our offerings. Second quarter of 2024 included $17 million of favorable performance-based fee adjustments compared to $16 million of such adjustments in the second quarter of 2023. The ability to earn performance-based fees as we drive benefits for our clients is a favorable and an ongoing attribute of our healthcare business, though the recognition of revenue for such adjustments can vary significantly quarter-to-quarter. Operating margin for healthcare was 29.1% in Q2 2024 compared to 28.3% in Q2 2023. The increase in margin was primarily due to a decrease in contractor expenses, partially offset by an increase in compensation costs for our revenue-generating professionals as a percentage of revenues. The education segment generated 33% of total company revenues during the second quarter of 2024. The education segment posted revenues of $122.8 million, up $12.1 million or 10.9% from the second quarter of 2023 and included $6.8 million from our acquisition of GG+A. The increase in revenues in the quarter was driven by increased demand for our strategy and operations and digital product offerings. Education's consulting and managed services capability revenue grew 19% over the second quarter of 2023. The operating margin for education was 25.1% for Q2 2024 compared to 24.8% for the same quarter in 2023. The increase in operating margin in the quarter was primarily driven by revenue growth that outpaced increasing compensation costs for our revenue-generating professionals and a decrease in contractor expenses, partially offset by an increase in compensation cost for our support personnel as a percentage of revenue. The commercial segment generated 16% of total company revenues during the second quarter of 2024. We posted revenues of $58.8 million compared to $62.3 million in the second quarter of 2023. The decrease in revenues was driven by a slower sales cycle for our digital offerings, partially offset by an increase in demand for our financial advisory offerings. As Mark mentioned, despite the shorter term softening of market demand for our digital offerings, we are confident in the long-term growth trajectory of the commercial segment, temporary macro headwinds ease, and we fully capture the ongoing strength in our sales pipeline. Operating margin for the commercial segment was 15.3% in Q2 2024 compared to 16.8% for the same quarter of 2023. The decrease in operating margin was driven by an increase in compensation costs for our revenue-generating professionals as a percentage of revenues, partially offset by decreases in restructuring charges and contractor expenses as a percentage of revenues. Corporate expenses not allocated at the segment level, excluding the $15 million litigation settlement gain and corporate restructuring charges, were $45.6 million in Q2 2024 compared to $43 million in Q2 2023. Unallocated corporate expenses in the second quarter of 2024 and 2023 included $700,000 and $1.4 million, respectively of expense related to the increase in the liability of our deferred compensation plan, which is offset by the investment gain on the assets used to fund that plan reflected in other income. Excluding the impact of the deferred compensation plan in both periods, unallocated corporate expenses increased $3.2 million, primarily due to increases in software and data hosting expenses and compensation expense for our support personnel. Now, turning to the balance sheet and cash flows. Cash flow from operations in the second quarter of 2024 was a record $107.2 million. In the quarter, we invested $9 million in capital expenditures, inclusive of internally developed software costs, resulting in free cash flow of $98.2 million. DSO was 81 days at the close of the second quarter of 2024 compared to 91 days for the first quarter of 2024 and 77 days for the second quarter of 2023. Total debt, as of June 30th, 2024, was $511.6 million consisting entirely of our senior bank debt and we end the quarter with cash of $17.6 million or net debt of $493.9 million. This was a $61.1 million decrease in net debt compared to Q1 of 2024. Our leverage ratio defined in our senior bank agreement was 2.2 times adjusted EBITDA as of June 30th, 2024, consistent with the leverage ratio as of June 30th, 2023. During the second quarter, we used $34.4 million to repurchase approximately 376,000 shares. Since the beginning of 2024, we have repurchased 1 million shares, representing 5.4% of our common stock outstanding as of December 31st, 2023. As of June 30th, 2024, $90 million remained available for share repurchases under our current share repurchase program. We achieved record free cash flow in the second quarter of 2024 and continue to execute on our balanced capital deployment strategy. We believe the cumulative effect of our return to shareholders via share repurchases over the last several years has well-positioned us for continued strong EPS expansion. At the same time, our balance sheet remains strong, providing us the capacity for continued share repurchases and accretive M&A. Finally, let me turn to our guidance for the full year 2024. As Mark mentioned, we are updating our full year 2024 revenue and earnings guidance as follows. Narrowing our revenues before reimbursable expenses guidance to a range of $1.46 billion to $1.5 billion, reflecting the lower half of our previous revenue guidance range; increasing our adjusted EBITDA as a percentage of revenue guidance to a range of 13% to 13.5%; and increasing our adjusted diluted earnings per share guidance to a range of $5.85 to $6.15. Thanks, everyone. I would now like to open the call to questions. Operator?